NEW YORK (GenomeWeb News) — Caprion Pharmaceuticals and Ecopia Biosciences have agreed to merge to form a new company that is focused on drug development, and then sell off Caprion’s proteomics business, the companies said today.
 
The firms said they expect to divest Caprion’s CellCarta proteomics unit within a year, and then will solely pursue oncology and infectious disease therapeutics. The new company will have three clinical therapeutic programs nearing commercialization, the companies said.  
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports

By sequencing two ancient dog genomes, researchers from the US and Germany suggest that dogs were domesticated in a single event, the Washington Post reports.

In Genome Research this week: population dynamics of E. coli infection, lncRNA expression changes in macaque aging, and more.

Noninvasive prenatal testing can uncover pregnancies at risk of miscarriage, New Scientist reports.